Melanotan-1: Risks & Legal Status

Critical Safety Information#

Melanotan-1 is a research compound that has not been approved for human use by any major regulatory agency. This page provides risk information for educational purposes only.

Growth Factor and Angiogenesis Risks#

Growth factor/oncologic concerns

• Nevus darkening and morphological changes: In EPP patients receiving afamelanotide, dermoscopic changes of acquired melanocytic nevi (focal pigment network thickening and increased globules) occur by ~5 months and revert by 12 months, without malignant dermoscopic features or new nevi formation in the series studied (n=15 patients; 103 nevi). These findings prompted precautionary skin surveillance recommendations but do not demonstrate carcinogenicity.
• Incidence of new nevi and melanoma: Phase 3 and observational data summarized in a 2025 review report occasional new nevi with afamelanotide (2/86 in trials vs 1/81 placebo; 2 cases in an 8‑year observational cohort of 115), with no melanomas reported among >1000 afamelanotide‑exposed patients to date, many treated continuously ≥5 years.
• Case reports with unregulated melanotan products: Multiple reports link illicit melanotan (often Melanotan‑II) to eruptive nevi and melanomas, underscoring potential promotion of pre‑existing lesions, confounding from unregulated dosing, and differences from regulated afamelanotide.
• Mechanistic context: MC1R agonism increases eumelanin and can reduce UV‑induced DNA damage, but cAMP/ERK/Akt pathway overactivation is oncogenic in other contexts and melanin’s redox properties may be pro‑oxidant; these concerns remain theoretical for afamelanotide with current human data.

Immune modulation risks

• Anti‑inflammatory/immunosuppressive signaling: Afamelanotide/α‑MSH agonism inhibits pro‑inflammatory cytokines and is associated with stimulation of DNA repair; reviews describe α‑MSH as an inducer of IL‑10 and an immunoregulatory peptide, indicating potential to dampen immune responses.
• Clinical immunogenicity/infection signals: Longitudinal afamelanotide experience did not show increasing anti‑drug antibody reactivity, and available clinical reports do not identify a clear signal for increased infections or autoimmunity; thus, immunomodulation is mechanistically plausible but not yet associated with excess clinical infectious risk in regulated use. Editorial/regulatory statements warn that illicit melanotan products could harm immune and cardiovascular systems, reinforcing theoretical risk outside regulated contexts.

Quality control and peptide sourcing issues

• Unlicensed/underground market: Products marketed as “melanotan” are widely sold online and in informal settings despite being unapproved; regulators in multiple countries (FDA, MHRA, Danish, Norwegian, Swedish agencies) have formally warned consumers to avoid these products.
• Mislabeling/substitution: Items labeled as “melanotan” or “melanotan‑1” are frequently Melanotan‑II or other compounds, with no assurance of identity, purity, or potency; originator communications emphasize these are unrelated to the licensed afamelanotide product.
• Contamination and sterility breaches: The Irish Medicines Board detected microbial contamination in a vial of water sold with melanotan powder, indicating real infection risk from non‑GMP supply chains.
• Clinical signals from unregulated products: Reports document darkening/enlargement of moles and eruptive nevi following internet‑sourced melanotan use, plausibly reflecting dose/formulation variability and unknown impurities; these events underpin regulator warnings and differ from the safety profile of regulated afamelanotide.

Interpretation

• In regulated, clinically indicated use (EPP), afamelanotide shows reversible nevus darkening without malignant features, very low incidence of new nevi, and no melanoma signal across >1000 exposed patients, though precautionary skin surveillance is advised and long‑term carcinogenicity remains a monitored, theoretical concern.
• Afamelanotide and α‑MSH signaling exert anti‑inflammatory/IL‑10–linked effects that could, in theory, modulate host defense; however, trials have not shown increased immunogenicity or a clear infection/autoimmunity signal to date.
• The major safety risks arise with unregulated “melanotan” sourcing: mislabeling/substitution (often MT‑II), lack of GMP controls, documented contamination, and reported adverse changes in melanocytic lesions—collectively prompting strong regulatory warnings to avoid such products.

Embedded summary table:

Regulatory and Legal Status#

United States (FDA)

• Status: Approved. The FDA approved afamelanotide (SCENESSE) in October 2019 for adults with erythropoietic protoporphyria (EPP) to increase pain‑free light exposure. The product is a subcutaneous, bioabsorbable implant formulation.
• Notes: The gathered evidence confirms approval timing and indication but does not detail specific FDA program elements (e.g., REMS or orphan designation) or later regulatory changes.

European Union (EMA)

• Status: Approved. The EMA granted centralized marketing authorisation in December 2014 for symptomatic treatment of EPP. Recommended use is a 16 mg subcutaneous implant approximately every 60 days, with post‑authorisation safety monitoring described.
• Notes: Sources describe EMA approval and dosing; they mention ongoing safety monitoring but do not cite later EMA regulatory changes in this evidence set.

Australia (TGA)

• Status: Approved. The TGA approved afamelanotide in October 2020 for EPP.
• Notes: No further Australia‑specific regulatory changes are reported in the gathered evidence.

United Kingdom (MHRA)

• Status: Undetermined in this evidence set. The gathered sources do not provide MHRA licensing documentation or explicit post‑Brexit MHRA status.
• Notes: While some literature discusses European (EMA) approval and general access/assessment topics, MHRA-specific authorisation details are not present in the retrieved evidence.

Canada (Health Canada)

• Status: Undetermined in this evidence set. No Health Canada approval or denial was identified in the gathered sources.

Legal status of unapproved “melanotan” tanning products

• The retrieved evidence addresses afamelanotide (Melanotan‑1) approvals for EPP but does not provide regulator statements about the legality of unapproved “melanotan” products marketed for tanning. Therefore, legal status of such products in the US, EU/UK, Australia, or Canada cannot be concluded from this evidence set.

Most recent regulatory changes identifiable here

• The most recent dated approval event in this evidence is Australia’s TGA approval in October 2020. No subsequent jurisdiction‑specific changes (labeling updates, program changes) are documented in the gathered sources.

Notes on evidence strength and gaps

• Multiple peer‑reviewed sources consistently report EMA approval in 2014, FDA approval in 2019, and TGA approval in 2020.
• This evidence set does not include primary regulator documents (e.g., FDA label/approval letter, EMA EPAR, TGA ARTG public summary) or UK/Canada regulator records; thus, MHRA and Health Canada statuses and any detailed FDA/EMA program elements or recent updates remain unverified within this corpus.

At-Risk Populations#

• Pregnancy/lactation: Highest caution. Afamelanotide trials excluded women of child‑bearing potential and withdrew for suspected pregnancy; peer‑reviewed reviews emphasize limited human data. Avoid unless clear benefit with specialist oversight.
• Current or prior melanoma/skin cancer or high‑risk nevi: Elevated concern. Trials in vitiligo excluded any melanoma/lentigo maligna, dysplastic nevus syndrome, or malignant skin lesions; EPP trials recorded melanocytic nevi as AEs. Long‑term EPP data and expert reviews report no melanoma signal to date, and a dermoscopic study shows reversible nevus darkening; nevertheless, case reports with unregulated melanotan peptides describe melanomas/atypical nevi. Prefer avoidance or strict dermatologic surveillance.
• Other active cancers: Caution. No direct clinical evidence of harm, but mechanistic and case‑report literature raises theoretical concerns about melanocortin signaling and tumor–immune interactions; consider oncology input before use.
• Immunocompromised (HIV, transplant, immunosuppressants): Caution. Direct afamelanotide data are lacking. Immunosuppressed patients carry elevated background skin‑cancer risk; theoretical α‑MSH immunomodulation argues for careful risk–benefit and close skin surveillance.
• Anticoagulants/antiplatelets: Procedural bleeding risk. Afamelanotide is delivered by a subcutaneous implant via a 14‑gauge catheter; trials document implant‑site discoloration and pain. While no anticoagulant‑specific analysis was found, peri‑procedural hematoma risk should be considered and managed (compression, timing of high‑risk agents).

Key evidence and interpretation

• Pregnancy: In pivotal EPP trials, a participant discontinued for suspected pregnancy, reflecting exclusion/avoidance in study designs; contemporary clinical reviews note limited pregnancy data and emphasize post‑authorization surveillance rather than established safety, supporting a precautionary stance.
• Cancer risk and nevi: The vitiligo RCT explicitly excluded patients with a history of melanoma/lentigo maligna, dysplastic nevus syndrome, or any malignant skin lesion, indicating investigator concern for these groups. In EPP RCTs, melanocytic nevi and pigmentation disorders were captured as AEs, but events were few, and no melanoma signal emerged. A dermoscopic study in afamelanotide‑treated adults documented transient, reversible nevus changes without malignant features. A long‑term observational EPP cohort (≥8 years; 314 patient‑years) reported good tolerability and no evidence that afamelanotide causes malignancy; authors frame skin cancer listing as precautionary (biolcati2015long‐termobservationalstudy pages 8-9). Mechanistic/clinical reviews similarly report no melanoma cases to date in regulated afamelanotide programs, though they acknowledge ongoing monitoring. In contrast, case reports involving unregulated melanotan‑II (and some MT‑I contexts) describe temporal associations with melanoma/atypical or eruptive nevi, underscoring caution in patients with prior melanoma or high‑risk nevi.
• Immunocompromise: No afamelanotide trials specifically evaluate immunocompromised cohorts. Given the higher incidence of skin cancers under immunosuppression and theoretical α‑MSH anti‑inflammatory effects, individualized assessment and dermatologic follow‑up are prudent.
• Anticoagulants: Administration uses a subcutaneous implant with a 14‑gauge catheter; implant‑site discoloration and pain were observed in RCTs, so hematoma could be a plausible risk in anticoagulated patients even though no targeted analyses were identified.

Clinical framing

• Highest risk/avoid: pregnancy and breastfeeding (insufficient data); patients with current melanoma or active malignant skin lesions. If considered in patients with a history of melanoma/skin cancer or high‑risk nevi, involve dermatology and institute baseline and periodic skin exams.
• Elevated caution: other active cancers (seek oncology input); immunocompromised states (heightened background skin‑cancer risk; ensure close surveillance).
• Procedural caution: those on anticoagulants/antiplatelets (optimize peri‑implant timing and compression to mitigate hematoma risk).

Supporting summary table

Risk Mitigation#

For Researchers#

1. Use only from verified, third-party tested sources
2. Follow proper handling and sterility protocols
3. Document all observations carefully
4. Report adverse events

General Precautions#

1. Consult healthcare providers before any use
2. Start with lowest suggested amounts in research protocols
3. Monitor for any adverse effects
4. Discontinue immediately if problems arise

Related Reading#

• Melanotan-1 overview and research guide
• Melanotan-1 side effects profile
• Melanotan-1 research evidence